维生素D在脑血管痉挛治疗中的新视角
该研究通过回顾性和前瞻性临床分析结合小鼠蛛网膜下腔出血模型及细胞培养实验,探讨维生素D系统对脑血管痉挛的治疗潜力。回顾性分析显示冬季维生素D低谷期蛛网膜下腔出血患者血管痉挛频率增加,前瞻性数据表明血管痉挛严重程度与血浆维生素D水平呈负相关。机制上1,25-二羟维生素D3通过诱导SDF1α减轻小鼠血管痉挛、神经功能缺损和炎症。
要点
- 蛛网膜下腔出血后血管痉挛严重程度与血浆维生素D水平呈负相关
- 1,25-二羟维生素D3通过诱导SDF1α减轻小鼠血管痉挛和炎症
- 维生素D给药应作为预防血管痉挛的可选治疗进行测试
核心结论
- 1,25-二羟维生素D3通过诱导SDF1α减轻蛛网膜下腔出血后脑血管痉挛。
- 维生素D给药应作为预防血管痉挛的可选治疗进行测试。
研究设计与样本
- 回顾性分析2007至2015年检测的25-维生素D3水平及维生素D3峰值月与低谷月入院的蛛网膜下腔出血患者数据。
- 前瞻性关联2017年入院的蛛网膜下腔出血患者维生素D3与血管痉挛/结局数据。
- 使用小鼠蛛网膜下腔出血模型和细胞培养模型研究1,25-二羟维生素D3的作用。
主要发现
- 回顾性分析显示冬季维生素D低谷期蛛网膜下腔出血患者血管痉挛频率增加。
- 活性1,25-二羟维生素D3减轻小鼠鞘内注血后的血管痉挛、神经功能缺损和炎症。
- 内皮或髓系细胞中维生素D受体缺失减弱1,25-二羟维生素D3的保护作用。
- 髓系与内皮细胞共培养证实1,25-二羟维生素D3的抗炎作用并揭示其诱导SDF1α、血管内皮生长因子和内皮型一氧化氮合酶。
- 小鼠中SDF1α模拟1,25-二羟维生素D3对血管痉挛的保护作用。
临床怎么用
- 监测蛛网膜下腔出血患者血浆维生素D水平可能有助于评估血管痉挛风险。
- 维生素D给药作为预防血管痉挛的可选治疗尚需进一步临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cerebral vasospasm (CVS) is a frequent complication after subarachnoid hemorrhage (SAH), with no sufficient therapy and a complex pathophysiology. OBJECTIVE: To explore the vitamin D system as a potential treatment for CVS. METHODS: 25-vitamin D3 levels tested between 2007 and 2015 and data of SAH patients admitted during the months with a peak vs nadir of VitD3 values were analyzed, retrospectively. We prospectively correlated VitD3 and vasospasm/outcome data in SAH patients admitted in 2017. An experimental mice SAH model and cell culture model were used to investigate the effect of 1,25-dihydroxyvitamin D3 (1,25-VitD3). Additionally, the mediators acting in the VitD mechanism were researched and detected. RESULTS: Based on the retrospective analysis demonstrating an increased frequency of vasospasm in SAH patients during the low vitamin D period in winter, we started basic research experiments. Active 1,25-VitD3 hormone attenuated CVS, neurological deficit, and inflammation after intrathecal blood injection in mice. Deletion of the vitamin D receptor in the endothelium or in myeloid cells decreased the protective 1,25-VitD3 effect. Co-culture experiments of myeloid and endothelial cells with blood confirmed the anti-inflammatory 1,25-VitD3 effect but also revealed an induction of stroma-cell-derived factor 1α (SDF1α), vascular endothelial growth factor, and endothelial nitric oxide synthase by 1,25-VitD3. In mice, SDF1α mimicked the protective effect of 1,25-VitD3 against CVS. From bench to bedside, CVS severity was inversely correlated with vitamin D plasma level, prospectively. Patients with more severe CVS exhibited attenuated expression of SDF1α and 1,25-VitD3-responsive genes on circulating myeloid cells. CONCLUSION: 1,25-VitD3 attenuates CVS after SAH by inducing SDF1α. However, VitD administration should be tested as optional treatment to prevent CVS.
引用
- Kashefiolasl S, Leisegang MS, Helfinger V, et al. Vitamin D-A New Perspective in Treatment of Cerebral Vasospasm. Neurosurgery. 2021. PMID: 33269399. doi:10.1093/neuros/nyaa484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。